Connection

W. Garvey to Risk Factors

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Risk Factors.
W. Garvey
Connection Strength
0.630
Risk Factors
  1. Covid-19 & Obesity: Beyond Bmi. Endocr Pract. 2020 Aug; 26(8):923-925.
    View in: PubMed
    Score: 0.087
  2. Relationship of Circulating miRNAs with Insulin Sensitivity and Associated Metabolic Risk Factors in Humans. Metab Syndr Relat Disord. 2018 03; 16(2):82-89.
    View in: PubMed
    Score: 0.073
  3. Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc. 2016 07 13; 5(7).
    View in: PubMed
    Score: 0.065
  4. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016 Feb; 24(2):516-25.
    View in: PubMed
    Score: 0.063
  5. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. J Clin Endocrinol Metab. 2015 Oct; 100(10):3871-7.
    View in: PubMed
    Score: 0.061
  6. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014 Jan; 22(1):110-8.
    View in: PubMed
    Score: 0.054
  7. Intramyocellular lipid and insulin resistance: differential relationships in European and African Americans. Obesity (Silver Spring). 2011 Jul; 19(7):1469-75.
    View in: PubMed
    Score: 0.045
  8. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004 Apr; 27(4):978-83.
    View in: PubMed
    Score: 0.028
  9. Case presentation and panel discussion: Cardiometabolic risk mitigation. JPEN J Parenter Enteral Nutr. 2021 11; 45(S2):93-99.
    View in: PubMed
    Score: 0.024
  10. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.016
  11. Cardiovascular risk in Gullah African Americans with high familial risk of type 2 diabetes mellitus: project SuGAR. South Med J. 2014 Oct; 107(10):607-14.
    View in: PubMed
    Score: 0.014
  12. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.013
  13. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012; 7(11):e48852.
    View in: PubMed
    Score: 0.013
  14. Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Relat Disord. 2012 Aug; 10(4):244-51.
    View in: PubMed
    Score: 0.012
  15. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7):933-46.
    View in: PubMed
    Score: 0.010
  16. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.009
  17. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications. 2008 May-Jun; 22(3):153-63.
    View in: PubMed
    Score: 0.009
  18. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 2005 Jan-Feb; 19(1):18-25.
    View in: PubMed
    Score: 0.007
  19. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004 Oct; 53(10):1296-304.
    View in: PubMed
    Score: 0.007
  20. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes. 2003 May; 52(5):1215-21.
    View in: PubMed
    Score: 0.007
  21. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar; 26(3):810-8.
    View in: PubMed
    Score: 0.006
  22. Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. Ethn Dis. 2000; 10(1):17-23.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.